linjc16/ctgov huggingface dataset:
A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma

Study Overview
=================
Brief Summary
-----------------
This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety of SGN-75 in patients with CD70-positive relapsed or refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.

Official Title
-----------------
A Phase 1, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Patients With CD70-positive Relapsed or Refractory Non-Hodgkin Lymphoma or Metastatic Renal Cell Carcinoma

Conditions
-----------------
Carcinoma, Renal Cell, Lymphoma, Non-Hodgkin

Intervention / Treatment
-----------------
* Drug: SGN-75


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pathologically-confirmed diagnosis of NHL or RCC Relapsed, refractory, or progressive disease following at least 1 prior systemic therapy Confirmed CD70 expression Measurable disease, defined as at least 1 lesion >1.5 cm in the greatest transverse diameter for patients with NHL, and at least 1 non-resectable tumor lesion > or equal to 10 mm in diameter for patients with RCC Exclusion Criteria: Previously received an allogeneic transplant History of another primary malignancy that has not been in remission for at least 3 years Prior anti-CD70-directed therapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>SGN-75 | Drug: SGN-75<br>* SGN-75 (IV) in 21- or 28-day cycles; dose range: 0.3-9 mg/kg<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of adverse events and laboratory abnormalities |  | Through 1 month following last dose | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Best clinical response |  | Every 2 months | 
| Duration of response, progression-free survival |  | Every 3 months until progression of disease or initiation of new treatment for cancer | 
| Blood concentrations of SGN-75 and metabolites |  | Through 1 month following last dose | 
| Incidence of antitherapeutic antibodies |  | Through 1 month following last dose | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Antibodies, Monoclonal, Antibody-Drug Conjugate, Antigens, CD70, Lymphoma, Non-Hodgkin, Carcinoma, Renal Cell, Immunotherapy, Drug Therapy, monomethylauristatin F
Real-life EValuation Of High Dose RosUvastatin in High Risk Patients After TitraTION

Study Overview
=================
Brief Summary
-----------------
To evaluate achievement ratio of treatment target goal in hypercholesterolemia patients with high risk after high dose rosuvastatin(20mg/day) titration

Official Title
-----------------
An Observational, Non-interventional, Multi-center Study to Evaluate Efficacy and Tolerability of High Dose Rosuvastatin in High Risk Patients After Titration

Conditions
-----------------
Hypercholesterolemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: High-risk hyperlipidemia patients who are prescribed with rosuvastatin 10mg, based on the physician's clinical decision and fulfill the following criteria Over 18 years of age Have history of CHD or CHD risk equivalents, such as peripheral arterial disease, abdominal aortic aneurysm, symptomatic carotid artery disease (TIA or stroke of carotid origin or >50% obstruction of carotid artery), DM, and 2+ risk factors with 10-year risk CHD>20% Exclusion Criteria: Patients already taking other hyperlipidemic agents Patients who do not fulfil the indication criteria for statin therapy Patients who do not have baseline and/or follow-up lipid data to verify the efficacy data

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hypercholesterolemia, Crestor, LDL target goal, high risk patients, Naturalistic, Observational
EFFECTS OF ACUPUNCTURE ON LEG MUSCLE STRENGTH

Study Overview
=================
Brief Summary
-----------------
Press tack needle is one of the acupuncture modalities in the form of needles that are attached to the skin, and can be left attached to the skin for several days which makes its use much easier than conventional acupuncture. The purpose of this study was to determine how the effect of press tack needle acupuncture on leg muscle strength performed on sports students. Research subjects as many as 30 people were randomized into two groups, namely the intervention group and the control group. In the intervention group, acupuncture treatment was performed with a press tack needle at acupuncture points on the legs. The leg muscle strength was measured using a leg dynamometer before and after the acupuncture intervention. Analyzed the difference in mean leg muscle strength before and after the intervention, and between the two groups.

Official Title
-----------------
EFFECTS OF ACUPUNCTURE ON LEG MUSCLE STRENGTH: RANDOMIZED CONTROLLED TRIAL IN SPORTS STUDENTS

Conditions
-----------------
Health, Subjective, Muscle Strength

Intervention / Treatment
-----------------
* Device: Press tack needle
* Device: Plesterin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: willingness to fill out an informed consent form; age between 18-25 years; male; has a BMI value of 18.5-22.9 kg/m2; there is no history of injury or history of surgery on the lower extremities in the last three months; the individual is in good health. Exclusion Criteria: absence or refusal to be examined and not cooperative.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 25 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Acupuncture group<br>Intervention of press tack needle acupuncture | Device: Press tack needle<br>* Press tack needle acupuncture using Seirin Pyonex sized 0.20x1.2mm<br>|
| Placebo Comparator: Control group<br>Intervention of placebo acupuncture | Device: Plesterin<br>* Plesterin<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Leg muscle strength | Measurement of leg muscle strength before the intervention, and compared between the two groups | baseline (Before intervention) | 
| Leg muscle strength | Measurement of leg muscle strength after the intervention, and compared between the two groups | 35 minutes after intervention | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
acupuncture, press tack needle, leg strength
Clinical Applicability of the Device Belk in the Rehabilitation Process

Study Overview
=================
Brief Summary
-----------------
Pilot, interventional, randomized of parallel groups and multicenter clinical trial.

Official Title
-----------------
Clinical Applicability of the Device Belk in the Rehabilitation Process

Conditions
-----------------
Application Site Atrophy

Intervention / Treatment
-----------------
* Device: Belk Device
* Other: Standard Rehabilitative treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients of both sexes. Patients aged between 18 and 85 years. Patients with knee arthroplasty in the immediate postoperative period. Sign in informed consent. Exclusion Criteria: Physical or psychological pathologies that prevent patient participation. Tumor arthroplasty. Knee replacement prosthesis. Impossibility of holding the device. Patients with a pacemaker.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Belk Device<br>With Belk Device | Device: Belk Device<br>* Knee exoskeleton with electrostimulation<br>|
| Other: Standard Rehabilitative treatment<br>With the standard rehabilitative treatment | Other: Standard Rehabilitative treatment<br>* Use the standard rehabilitative treatment<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of sessions until recovery | It is considered that the patient has completed the rehabilitation treatment when he has achieved an arc of movement between 0 and 100 degrees of flexion, a quadriceps muscle balance greater than or equal to 4/5 according to MRC (Medical Research Council)and a stable march with crutches. | An average of 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| March in 10 meters | Number of patients can be walk 10 meters | An average of 12 weeks | 
| UP&Go test | Do the UP&GO test | An average of 12 weeks | 
| Number of falls during rehabilitation sessions | Number of falls during rehabilitation sessions | An average of 12 weeks |
Idiopathic Pulmonary Fibrosis Registry for Future Studies

Study Overview
=================
Brief Summary
-----------------
To establish a registry of patients for future studies of Inflammation in Interstitial Lung Disease/Idiopathic Pulmonary Fibrosis.

Detailed Description
-----------------
To establish a framework in which biologic samples and physiologic measures from patients with IPF can be longitudinally collected and evaluated. Having a bank of samples that are correlated with physiologic measures that follow patients through their course will allow the following proposed studies as well as future investigations to be efficiently carried out.

Official Title
-----------------
Inflammation in Interstitial Lung Disease/Idiopathic Pulmonary Fibrosis

Conditions
-----------------
Lung Disease, Interstitial, Idiopathic Pulmonary Fibrosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: any patient referred to the Interstitial Lund Disease clinic who is undergoing evaluation and or treatment for a new diagnosis of ILD. This can include patients referred for presumed pulmonary fibrosis/interstitial pneumonitis (IPF, UIP, NSIP), sarcoidosis, hypersensitivity pneumonitis, cryptogenic organising pneumonia, drug-induced, or other idiopathic ILDs. Exclusion Criteria: pregnancy inability to follow study requirements

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Framework | To establish a framework in which biologic samples and physiologic measures from patients with IPF can be longitudinally collected and evaluated | 7 + years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
IPF
Women and Risk of Type 2 Diabetes

Study Overview
=================
Brief Summary
-----------------
This is a follow-up survey of women, 10-12 years after they were included in the population-based Stork Groruddalen study of pregnant women, primarily set up to study gestational diabetes and related health issues in pregnancy in a multiethnic population. The investigators will now update the information about the health status of these women to study the development of risk factors for type 2 diabetes and cardiovascular diseases.

Detailed Description
-----------------
The STORK-Groruddalen is a cohort study of 823 pregnant women. Participation rate was high due to facilitation for ethnic minorities and data collection at the local Health Centres, set up to study ethnic differences in health to inform prevention strategies to reduce these differences. The investigators have published many papers from this well charatertized cohort, about gestational diabetes and related health issues in pregnancy. Participants have agreed to be contacted for subsequent follow-up surveys. The inivestigators are now planning a follow-up study of these woman during 2019-2022, to study trajectories for risk factors for type 2 diabetes and cardiovascular diseases such as BMI, blood pressure, lipids, behavioural factors, physical activity and mental health and other health issues. The investigators will collect selfreported information through questionnaires, perform clinical measurements and take blood samples and buccal swabs. Collecting updated information about a range of health outcomes for women in this cohort will, together with already collected data, enable us to study the development of risk factors for type 2 diabetes and cardiovascular diseases in a life course perspective.

Official Title
-----------------
Women and Risk of Type 2 Diabetes

Conditions
-----------------
Type 2 Diabetes Mellitus

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Previous participants in the STORK G study still living in Norway Exclusion Criteria: Moved out of Norway

Ages Eligible for Study
-----------------
Minimum Age: 27 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Type 2 diabetes | Prevalence | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Prevention, Cardiovascular diseases, Physical activity, Ethnic differences in health, Risk factors
Diagnostic Scoring for Small Bowel Obstruction

Study Overview
=================
Brief Summary
-----------------
It is difficult to predict which patients with acute small bowel obstruction require operative intervention and which ones can be handled conservatively. Similarly, strangulation remains difficult decision. The rationale for this observative study is to collect prospective cohort of patients with small bowel obstruction to create scoring system to predict early 1) small bowel obstruction resistant to conservative therapy, 2) strangulation.

Official Title
-----------------
Diagnostic Scoring for Small Bowel Obstruction

Conditions
-----------------
Small Bowel Obstruction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Computed tomography verified acute small bowel obstruction Exclusion Criteria: < 18 years old Pregnant Abdominal surgery within 30 days prior recruitment Inflammatory bowel disease Small bowel tumor causing obstruction Peritoneal carcinosis Intraluminal obstruction (bile stone, bezoar, etc.) Large bowel obstruction Small bowel obstruction caused by abdominal wall hernia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 120 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Strangulation | Number of patients with strangulated bowel (reversible or irreversible ischemic bowel) | Within hospital stay / 30 days from recruitment | 
| Need for surgery due to nonresolving small bowel obstruction | Number of patients needing surgery due to nonresolving small bowel obstruction | Within hospital stay / 30 days from recruitment |
Long Time Metabolic Changes Induced by Genetically Modified Potatoes

Study Overview
=================
Brief Summary
-----------------
In this study the effects of genetically modified potatoes on the human metabolism will be observed. Healthy volunteers receive for one week muffins, produced with starch from a genetically modified potato or with a normal available starch, in a randomized trial.

Conditions
-----------------
Glucose Metabolism, Hormonal Changes, Satiety

Intervention / Treatment
-----------------
* Other: Genetically modified potato


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy male volunteers Exclusion Criteria: acute oder severe chronic diseases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Genetically modified potato|Genetically modified potato|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| glucose metabolism |  | 1 week |
A Study of the Effect of Mental Health Promotion on Mental Health Index

Study Overview
=================
Brief Summary
-----------------
Health includes physical and mental aspects. The evaluation of Mental Health contains four domains: psychophysical health, perceived security of the living world, meaning and worth of life, satisfaction of family-social interaction. We have established a Taiwan Mental Health Index scale based on literature review and experts' opinions in 2002. The reliability and validity were assessed to be satisfactory. This TMHI scale has been applied in nation-wide mental health surveys of 2002, 2003, and 2004. In order to evaluate the effect of mental health promotion activities, this research project will adopt this TMHI scale as the assessment tool. 300 people will be recruited for study after signing the informed consent. The general population sample of 1076 subjects recruited in 2004, will be as the comparison sample. The difference in 4 dimensions of MHI will be analyzed between these two study groups. The 300 study subjects will be subcategorized into two groups of low and high attendance groups. The difference in MHI between groups will also be statistically examined using independent t-test. The statistical signification is set at α=0.05. This study result will be as the reference for setting up effective mental health promotion program for general public.

Official Title
-----------------
A Study of the Effect of Mental Health Promotion on Mental Health Index

Conditions
-----------------
Healthy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Normal people education years over 9 years with reading ability Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
psychophysical health, Mental Health Promotion, Mental Health Index, Taiwan Mental Health Index scale, education years over 9 years, normal people, especially joining Mental Health Foundation Promotions
Multiple Dose Study of MPC-6827 in Subjects With Refractory Brain Metastases

Study Overview
=================
Brief Summary
-----------------
Phase 1, Multiple dose Study of MPC-6827 in Subjects with Refractory Brain Metastases.

Official Title
-----------------
Phase 1 Open Label, Dose Escalating, Multiple Dose Study to Determine the Safety, Tolerability, Maximum Tolerated Dose, and Pharmacokinetics of MPC-6827 Administered IV Weekly X 3, Repeated Every 28 Days, in Subjects With Refractory Brain Metastases

Conditions
-----------------
Brain Neoplasms

Intervention / Treatment
-----------------
* Drug: MPC-6827


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Refractory Brain Metastases At least 1 measurable intracranial lesion as defined by RECIST ECOG less than or equal to 1 Adequate hematology/organ function No baseline peripheral or central neuropathy above grade 1 Exclusion Criteria: Hypersensitivity to Cremophor EL Pregnant or Lactating Spinal Cord Compression Pre-existing dementia/cognitive disfunction Require Neupogen or Neulasta to Maintain Neutrophil Count Have Primary Brain Cancer Have History of Ischemic Heart Disease Have Diabetes

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: MPC-6827|2-hour IV infusion given once weekly for 3 consecutive weeks on a 28-day cycle.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Maximum Tolerated Dose |  | 1 year | 
| Pharmacokinetics |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Antitumor Activity |  | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Metastases, Refractory, Brain